METHOD OF PRODUCING A COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISEASES

Abstract

A method of producing a composition for a treatment of cardiovascular and cerebrovascular diseases is provided. The method includes the following steps of: a) according to a ratio of 1 lt, adding 2 ml 36.5-37.5% formic aldehyde solution to 998 ml sterile and 0.85-0.95% isotonic sodium chloride solution to obtain a mixture, mixing the mixture thoroughly and obtaining an aldehyde solution with a final concentration of 0.073-0.075% by weight for injection, and b) storing the composition obtained in a dark place at a temperature of 15-35° C.

Claims

1. A method of producing a composition for a treatment of cardiovascular and cerebrovascular diseases, comprising the following steps of: a) according to a ratio of 1 lt, adding 2 ml 36.5-37.5% formic aldehyde solution to 998 ml sterile and 0.85-0.95% isotonic sodium chloride solution to obtain a mixture, mixing the mixture thoroughly and obtaining an aldehyde solution with a final concentration of 0.073-0.075% by weight for injection; and b) storing the composition obtained in a dark place at a temperature of 15-35° C.

2. The method according to claim 1, wherein the composition comprises an oral and/or intramuscular administration of an obtained aqueous formic aldehyde solution.

Description

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0017] In this detailed description, preferred alternatives to the composition production method for the treatment of cardiovascular and cerebrovascular diseases according to the invention are described solely for a better understanding of the subject and without any limiting effect.

[0018] The production method of the composition of the invention is as follows; [0019] a) 2 ml 36.5-37.5% formic aldehyde solution, 998 ml sterile 0.85-0.95% sodium chloride solution, 0.073-0.075% aldehyde solution for injection are obtained according to 1 lt ratio. [0020] b) The composition obtained is stored in a dark place at a temperature of 15-35° C.

[0021] For example; 0.2 ml of 37% formic aldehyde solution is added to 998 ml of sterile and 0.90% or 0.95% isotonic sodium chloride solution to thoroughly mix the mixture to obtain a final concentration of 0.074% by weight formic aldehyde.

[0022] As another example; 0.2 ml of 36.5% formic aldehyde solution is added to 998 ml of sterile and 0.90% or 0.95% isotonic sodium chloride solution to thoroughly mix the mixture to obtain a final concentration of 0.073% by weight formic aldehyde.

[0023] Aqueous formic aldehyde solution (formic acid aldehyde) is a clear, colorless liquid with a distinct pungent odor that can be mixed with water and alcohol in all proportions. Formic aldehyde is a representative of the HCHO aldehyde class. It is a colorless gas with a pungent odor. It weighs 30.03, its density at −20° C. is 0.815 g/cm3, its melting point is −92° C. and its boiling point is −19.2° C. It is soluble in water and alcohol.

[0024] Isotonic sodium chloride solution is a colorless transparent liquid with salt. The solution is sterile, pyrogen-free.

[0025] Sodium chloride, cubic crystals or white crystalline powder, salty tasteless and odorless. It is soluble in water.

[0026] The aqueous formic aldehyde solution obtained with the composition of the invention is a clear, colorless, odorless liquid with a slightly salty taste.

[0027] The aqueous formic aldehyde solution obtained with the composition of the invention is administered orally and/or intramuscularly.

[0028] 5 ml is administered by injection once a day on days 1, 3, 7, 10, 14.

[0029] When administered orally, the composition is drunk for 10 ml in the morning and evening on an empty stomach 1/1.5 hours before or after a meal.

[0030] The composition of the invention is applied for 5, 7 or 10 days. It can be repeated 10, 20 or 30 days after the last application. The repetition of oral and/or intramuscular administration is decided according to the patient's clinical and biochemical parameters, taking into account the physiological condition.

[0031] In the injection of formic aldehyde into the body at the determined concentration ratio, the level of changes in the rate of glycolysis in the cytoplasm of the cells and the normalization of the physiological state of the cardiovascular system cells by aerobic oxidation related to mitochondrial activity were achieved.